Diabetes Researchers Gather: Agenda Remains a Mystery
Published Date: 12/5/2025
Notice
Summary
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is holding a virtual meeting on January 13-14, 2026, to review research progress and discuss grant applications. Scientists, researchers, and grant applicants will be affected as some sessions are open to the public while others are private to protect personal info. This meeting helps decide funding and research directions but doesn’t announce new money or deadlines yet.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Closed Grant-Review Sessions for Researchers
The NIDDK meeting on January 13-14, 2026 will include multiple closed sessions to review, discuss, and evaluate individual grant applications and investigators’ qualifications (closed under 5 U.S.C. 552b(c)(4) and 552b(c)(6)). The notice says these sessions protect personal privacy and that the meeting helps decide funding and research directions, but it does not announce new money or application deadlines.
Public Attendance and Campus Security Rules
Open portions of the meeting are available to the public on January 13 and 14, 2026 but attendance is limited to space available. Visitors to on-campus or off-campus NIH facilities will be subject to NIH security procedures (vehicle inspections, one form of photo ID required, and being asked the purpose of the visit).
Accommodations for Attendees with Disabilities
If you plan to attend and need special assistance (for example, sign language interpretation), you should notify the Contact Person listed in the notice in advance of the January 13-14, 2026 meeting so reasonable accommodations can be arranged.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-22131, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by February 3, 2026, before these guides become final. These updates aim to speed up drug approvals and keep costs down for everyone.
Next: 2025-22133, Performance Review Board Members
The Small Business Administration just announced a fresh team of leaders for its Performance Review Board, replacing the old lineup from May 2025. This board helps review how well top officials are doing their jobs, so it affects SBA employees and leadership. No changes to pay or timing were mentioned, but the new members are ready to get to work immediately.